Welcome to our dedicated page for ASCENTAGE PHARMA GROUP INTERNATIONAL SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma Group International filed a report noting that its management will participate in three upcoming investor conferences. The related presentations and fireside chats will be available via webcasts on the Events page in the Investor Relations section of the company’s website.
The filing also reiterates that Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies, including its approved products Olverembatinib for chronic myeloid leukemia and Lisaftoclax for certain blood cancers, alongside multiple global Phase III trials and collaborations with major pharmaceutical companies and leading research institutions.
Ascentage Pharma Group International furnished a report highlighting its upcoming participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. Company management will join a fireside chat at 9:30 a.m. EST on Thursday, February 12, with a live webcast available through the Events page of its investor relations website.
The filing also reiterates that Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies. Its lead drug Olverembatinib is approved in China for multiple chronic myeloid leukemia indications and covered by the China National Reimbursement Drug List. A second approved product, Lisaftoclax, treats certain chronic lymphocytic leukemia/small lymphocytic lymphoma patients and supports several global registrational Phase III trials in hematologic malignancies and myelodysplastic syndromes.
Ascentage Pharma Group International filed a Form 6-K to share that its BTK-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the China Center for Drug Evaluation (CDE). This follows a prior IND clearance from the U.S. Food and Drug Administration.
The company plans a multicenter, open-label Phase I trial in patients with relapsed or refractory hematologic malignancies to assess safety, tolerability, pharmacokinetics, and preliminary efficacy. APG-3288, built on Ascentage’s PROTAC technology, is designed to degrade both wild-type BTK and multiple resistance-associated BTK mutants, potentially addressing treatment-resistant B‑cell cancers and complementing its existing hematology portfolio, including Olverembatinib and Lisaftoclax in China.
Ascentage Pharma Group International provided an update on its 2025 milestones and outlined its global innovation strategy for 2026 during a presentation at the 44th Annual J.P. Morgan Healthcare Conference.
The company highlighted commercial progress of its two core hematology products, Olverembatinib and Lisaftoclax, which it describes as driving a dual-engine growth model, alongside multiple global registrational Phase III trials in blood cancers and solid tumors.
Ascentage Pharma also announced U.S. FDA IND clearance for APG-3288, a next-generation BTK protein degrader developed on its PROTAC platform, and discussed advancing additional candidates including APG-5918, APG-2449, Alrizomadlin, and Pelcitoclax, with planned 2026 milestones across clinical development, commercialization in China, and early-stage global studies, while emphasizing that these products remain investigational outside approved indications.
Ascentage Pharma Group International filed a Form 6-K to share that the U.S. Food and Drug Administration has granted investigational new drug (IND) clearance for APG-3288, a novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader. APG-3288, developed using the company’s PROTAC technology, is designed to degrade both wild-type and mutant BTK associated with resistance to existing BTK inhibitors.
The company will conduct a global, multicenter, open-label Phase I study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed or refractory hematologic and B-cell malignancies. Ascentage highlights this clearance as a major expansion of its innovative pipeline and a strategic step in BTK-targeted therapies, complementing its existing approved products Olverembatinib and Lisaftoclax.
Ascentage Pharma Group International submitted a Form 6-K stating that on December 17, 2025 it issued a press release titled “Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference.” The report’s primary purpose is to furnish this press release as Exhibit 99.1 for U.S. investors.
Ascentage Pharma Group International furnished a Form 6-K highlighting two scientific updates for its Bcl-2 inhibitor lisaftoclax. The company reported that pivotal China registrational study data for lisaftoclax were presented in an oral report at the 2025 American Society of Hematology (ASH) Annual Meeting.
Ascentage also noted encouraging data from a Phase Ib/II study of lisaftoclax in venetoclax‑exposed patients with myeloid malignancies, which were shared at ASH 2025. Full details of these results are contained in press releases attached as Exhibits 99.1 and 99.2.
Ascentage Pharma Group International submitted a Form 6-K as a foreign private issuer for November 2025. The report mainly notes that on November 24, 2025 the company issued a press release titled “Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy”. A copy of this press release is furnished as Exhibit 99.1, making the scientific and clinical update available to investors through the U.S. disclosure system.
Ascentage Pharma Group International filed a Form 6-K as a foreign private issuer to furnish a company press release. The filing notes that on November 19, 2025, the company issued a release titled “Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025.” The press release itself is attached as Exhibit 99.1 to the report. This Form 6-K does not present financial results or transaction details; it primarily serves to formally provide the investor conference announcement to the market.
Ascentage Pharma Group International filed a Form 6-K noting plans to present clinical data at the 2025 American Society of Hematology (ASH) Annual Meeting. The company furnished two press releases dated November 3, 2025 and a Hong Kong Stock Exchange announcement dated November 4, 2025 as Exhibits 99.1, 99.2, and 99.3.
The disclosures state Ascentage will share results from multiple studies of olverembatinib and lisaftoclax, and additional data on APG-5918. One of the presentations has been selected for an oral report.